List, Alan F.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 2,663

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 1,319

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 961

Efficacy of Lenalidomide in Myelodysplastic Syndromes

List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine

Acute Myeloid Leukemia ResearchErythropoietin and Anemia Treatment

Cited by 880

Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes

Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 465

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: A proof-of-concept, case-control study

Gillis, N. K., Ball, M., Zhang, Q., Ma, Z., Zhao, Y., Yoder, S. J., Balasis, M. E., Mesa, T. E., Sallman, D. A., Lancet, J. E., et al. (2017) · The Lancet Oncology

Acute Myeloid Leukemia ResearchMultiple and Secondary Primary Cancers

Cited by 317

Induction of myelodysplasia by myeloid-derived suppressor cells

Chen, X., Eksioglu, E. A., Zhou, J., Zhang, L., Djeu, J., Fortenbery, N., Epling-Burnette, P., Van Bijnen, S., Dolstra, H., Cannon, J., et al. (2013) · Journal of Clinical Investigation

Immune cells in cancerAcute Myeloid Leukemia Research

Cited by 316

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Sallman, D. A., & List, A. (2019) · Blood

Inflammasome and immune disordersAcute Myeloid Leukemia Research

Cited by 273

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

for the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 259

Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys

Sekeres, M. A., Schoonen, W. M., Kantarjian, H., List, A., Fryzek, J., Paquette, R., & Maciejewski, J. P. (2008) · JNCI: Journal of the National Cancer Institute

Acute Myeloid Leukemia ResearchHematological disorders and diagnostics

Cited by 248

The thalidomide saga

Melchert, M., & List, A. (2007) · The International Journal of Biochemistry & Cell Biology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 246

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

Sekeres, M. A., Othus, M., List, A. F., Odenike, O., Stone, R. M., Gore, S. D., Litzow, M. R., Buckstein, R., Fang, M., Roulston, D., et al. (2017) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 237

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

Sallman, D. A., Komrokji, R., Vaupel, C., Cluzeau, T., Geyer, S. M., McGraw, K. L., Al Ali, N. H., Lancet, J., McGinniss, M. J., Nahas, S., et al. (2016) · Leukemia

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 231

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Sallman, D. A., McLemore, A. F., Aldrich, A. L., Komrokji, R. S., McGraw, K. L., Dhawan, A., Geyer, S., Hou, H.-A., Eksioglu, E. A., Sullivan, A., et al. (2020) · Blood

Acute Myeloid Leukemia ResearchCancer Immunotherapy and Biomarkers

Cited by 196

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

Makishima, H., Jankowska, A. M., Tiu, R. V., Szpurka, H., Sugimoto, Y., Hu, Z., Saunthararajah, Y., Guinta, K., Keddache, M. A., Putnam, P., et al. (2010) · Leukemia

Acute Myeloid Leukemia ResearchEpigenetics and DNA Methylation

Cited by 179

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

Sekeres, M. A., Gundacker, H., Lancet, J., Advani, A., Petersdorf, S., Liesveld, J., Mulford, D., Norwood, T., Willman, C. L., Appelbaum, F. R., et al. (2011) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 80

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Hunter, A. M., Komrokji, R. S., Yun, S., Al Ali, N., Chan, O., Song, J., Hussaini, M., Talati, C., Sweet, K. L., Lancet, J. E., et al. (2021) · Blood Advances

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation

Cited by 76

Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858

Eksioglu, E. A., Chen, X., Heider, K.-H., Rueter, B., McGraw, K. L., Basiorka, A. A., Wei, M., Burnette, A., Cheng, P., Lancet, J., et al. (2017) · Leukemia

Acute Myeloid Leukemia ResearchImmune cells in cancer

Cited by 66

Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)

Yun, S., Geyer, S. M., Komrokji, R. S., Al Ali, N. H., Song, J., Hussaini, M., Sweet, K. L., Lancet, J. E., List, A. F., Padron, E., et al. (2021) · Leukemia

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 49

A decade of progress in myelodysplastic syndrome with chromosome 5q deletion

List, A., Ebert, B. L., & Fenaux, P. (2018) · Leukemia

Acute Myeloid Leukemia ResearchProtein Degradation and Inhibitors

Cited by 49

Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome

Martinez-Høyer, S., Deng, Y., Parker, J., Jiang, J., Mo, A., Docking, T. R., Gharaee, N., Li, J., Umlandt, P., Fuller, M., et al. (2020) · Nature Cell Biology

Acute Myeloid Leukemia ResearchProtein Degradation and Inhibitors

Cited by 42

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML

Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia‐Manero, G., Rahmé, R., Winer, E. S., Lehmann‐Che, J., Roboz, G. J., Madelaine, I., et al. (2025) · HemaSphere

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 26

Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival

Sallman, D. A., Al Ali, N., Yun, S., Padron, E., Song, J., Hussaini, M. O., Talati, C., Sweet, K. L., Lancet, J. E., List, A. F., et al. (2018) · Blood

Acute Myeloid Leukemia ResearchEpigenetics and DNA Methylation

Cited by 12